Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AstraZeneca) D926PC00001 / TROPION-Breast02A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerDr Louise BordeleauOpen to recruitmentNCT05374512
(CCTG) MA.39 / TAILOR RTA randomized trial of regional radiotherapy in Biomarker low risk node positive breast cancer (TAILOR RT)Dr Timothy WhelanOpen to recruitmentNCT03488693
(CCTG) MA.40 / FINERA Double-Blind Placebo Controlled Randomized Phase III Trial of Fulvestrant and Ipatasertib as Treatment for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)Dr Nidhi Kumar-TyagiOpen to recruitmentNCT04650581
(Roche) WO43919 / INAVO121A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of
Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant In Patients With Hormone Receptor positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During Or After CDK4/6 Inhibitor and Endocrine Combination Therapy.
Dr Haider SamawiSuspended/On holdNCT05646862
OCOG-2019-RHEALRandomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)Dr Timothy WhelanOpen to recruitmentNCT04228991
OCOG-2021-ELISAProspective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined with Clinico-Pathological Features (ELISA Study)Dr Timothy WhelanOpen to recruitmentNCT04797299
Download PDF